Antibodies against Calsequestrin and Type XIII Collagen are Good Markers for Chronic Upper Eyelid Retraction

REFERENCES

• Bartley G B, Gorman C A. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol 1995; 119: 792–795
   PubMed Web of Science ®Google Scholar
• El Kaissi, Frauman A, Wall J R. Thyroid-associated ophthalmop-athyy—a practical guide to classification, natural history and management. Int Med Journal 2004; 34: 482–491
   Google Scholar
• Yamada M, Li A W, Wall J R. Thyroid-associated ophthalmopathy: Clinical features, pathogenesis and management. Crit Rev Clin Lab Sci 2000; 37: 523–549
   PubMed Web of Science ®Google Scholar
• Bartley G B, Fatourechi V, Kadrmas E F, Jacobsen S J, Ilstrup D M, Garrity J A, Gorman C A. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121: 284–290
   PubMed Web of Science ®Google Scholar
• Grove A S. Upper eyelid retraction and Graves’ disease. Ophthalmology 1981; 88: 499–506
   PubMed Web of Science ®Google Scholar
• Kubota S, Gunji K, Stolarski C, Kennerdell J S, Wall J. Reevaluation of the prevalences of serum autoantibodies reactive with “64−kDa eye muscle proteins” in patients with thyroid−associated ophthalmopathy. Thyroid 1998; 8: 175–179
   PubMedGoogle Scholar
• Salvi M, Scalise D. Upper eyelid retraction in the absence of other evidence for progressive ophthalmopathy is associated with eye muscle autoantibodies. Clin Immunol Immunopathol 1995; 74: 44–50
   PubMedGoogle Scholar
• Nunery W R, Martin R T, Heinz G W, Gavin T J. The association of cigarette smoking with clinical subtypes of ophthalmic Graves’ disease. Ophthal Plast Reconstr Surg 1993; 9: 77–82
   PubMed Web of Science ®Google Scholar
• Gopinath B, Musselman R, Beard N, Tani J, Adams C, Wall JR. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are sensitive and specific markers of ocular myopathy in patients with Graves’ disease. Clin Exp Immunol 2006; 145: 56–62
   PubMed Web of Science ®Google Scholar
• Tani J, Wall JR. Analysis–Can the development of thyroid-associated ophthalmopathy be explained by autoimmunity against eye muscle antigens?. CMAJ 2006; 17: 239–241
   Web of Science ®Google Scholar
• Gopinath B, Musselman R, Adams C, Tani J, Beard N, Wall JR. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves’ disease with and without ophthalmopathy–Correlation with clinical features. Thyroid 2006; 16: 967–974
   PubMed Web of Science ®Google Scholar
• De Bellis A. M, Coronella C, Sansone D, Conte M, Iorio S, Perrino S, Battaglia M, Bellastella G, Wall J R, Bellastella A, Bizzarro A. Serum antibodies to collagen XIII: A further good marker of active Graves’ ophthalmopathy. Clinical Endocrinology 2005; 62: 24–29
   PubMed Web of Science ®Google Scholar
• Werner S C. Modifications of the classification of eye changes of Graves’ disease: Recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 1977; 44: 203–204
   PubMed Web of Science ®Google Scholar
• Mourits M P, Koornneef L, Wiersinga W M, Prummel M F, Berghout A, Van Der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: A novel approach. Br J Ophthalmol 1989; 73: 639–644
   PubMed Web of Science ®Google Scholar
• Gunji K, Kubota S, Stolarski C, Wengrowicz S, Kennerdell JS, Salvi M, Wall JR. A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves’ disease is identified as the calcium binding protein calsequestrin. Autoimmunity 1999; 29: 19
   Google Scholar
• Gunji K, De Bellis A, Kubota S, Swanson J, Wengrowicz S, Cochran B, Ackrell A C, Salvi M, Bellastella A, Bizzarro A, Sinisi A, Wall J R. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 1999; 84: 1255–1262
   PubMed Web of Science ®Google Scholar
• Rootman J, Patel S, Berry K, Nugent R. Pathological and clinical study of Müller's muscle in Graves’ ophthalmopathy. Can J Ophthalmol 1987; 22: 32–36
   PubMed Web of Science ®Google Scholar
• Feldon S E, Levin L. Graves’ ophthalmopathy: V. Aetiology of upper eyelid retraction in Graves’ ophthalmopathy. Br J Ophthalmol 1990; 74: 484–485
   PubMed Web of Science ®Google Scholar
• Shih M J, Liao S L, Kuo K T, Smith T J, Chuang L M. Molecular pathology of Müller's muscle in Graves’ ophthalmopathy. J Clin Endocrinol Metab 2006; 91: 1159–1167
   PubMedGoogle Scholar
• Hagg P, Rehn M, Huhtala P, Vaisanen T, Tamminen M, Pihlajaniemi T. Type XIII collagen is identified as a plasma membrane protein. J Biol Chem 1998; 273: 15590–15597
   PubMed Web of Science ®Google Scholar
• Kasper M, Archibald C, De Bellis AM, Li AW, Yamada M, Chang H-S, Wall JR. Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy. Proc Intl Symp on Thyroid Associated Ophthalmopathy. Thyroid, Audrey Gwendolyn. Southern Illinois UP, KyotoJapan 2002; 12: 187–191, October 2000 (suppl.)
   Google Scholar
• Porter J D, Khanna S, Kaminski H J, Rao J S, Merriam A P, Richmonds C R, Leahy P, Li J, Andrade F H. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA 2001; 98: 12062–12067
   PubMed Web of Science ®Google Scholar